RIPK1 and cancer: Notably, the complete knockdown of RIPK1 in cancer cells results in profound alterations within the tumour microenvironment, characterised by increased infiltration of effector T cells, reduced presence of immunosuppressive myeloid cells, and augmented secretion of immune-stimulating cytokines.21